CVS HEALTH Corp
CVSNYSE · SIC 5912
$107.47
↑ +0.9%Jul 17 close · end-of-day
Price
1Y↑ +74.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$137.5B
Enterprise Value
$188.8B
P/E
47.1
P/S
0.3
P/B
1.8
EV/EBITDA
17.9
PEG
—
FCF Yield
5.4%
Dividend Yield
2.5%
Revenue (TTM)
$407.9B
Net Income (TTM)
$2.9B
Free Cash Flow (TTM)
$7.4B
Gross Margin
—
Operating Margin
1.5%
Net Margin
0.7%
ROE
3.8%
ROIC
3.9%
Debt / Equity
0.8
Net Cash
-$51.3B
Return 1Y
+76.0%
Company profile
CVS Health Corporation provides health services in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions. Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products. The company operates approximately 9,900 retail locations and 1,200 MinuteClinic locations.
- CEO
- Karen S. Lynch
- Sector
- Retail Trade
- Industry
- Retail
- Employees
- 300,000
- Headquarters
- Rhode Island
- Website
- cvshealth.com
Management & directors
- Clark James DavidSVP, Cont & Chief Acct Officer
- Compton-Phillips AmyEVP, Chief Medical Officer
- Newman BrianEVP, Chief Financial Officer
- Mandadi TilakEVP, Chief Exp & Tech Officer
- Capozzi Heidi BEVP and Chief People Officer
- Joyner J. DavidPresident, CEO and Chair
- Khichi Samrat S.EVP, CPO and General Counsel
- Nelson Steven HEVP and President, Aetna
- Shah Prem SEVP and Group President
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-08-05
CVS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$100.4B↑ +6.2%
Diluted EPS$2.30↑ +63.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $268.7B | $292.1B | $322.5B | $357.8B | $372.8B | $402.1B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $13.9B | $13.3B | $8.0B | $13.7B | $8.5B | $4.7B |
| Net income | $7.2B | $8.0B | $4.3B | $8.3B | $4.6B | $1.8B |
| Diluted EPS | $5.46 | $6.02 | $3.26 | $6.47 | $3.66 | $1.39 |
| Operating cash flow | $15.9B | $18.3B | $16.2B | $13.4B | $9.1B | $10.6B |
| Free cash flow | $13.4B | $15.7B | $13.4B | $10.4B | $6.3B | $7.8B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 5.2% | 4.6% | 2.5% | 3.8% | 2.3% | 1.2% |
| Net margin | 2.7% | 2.7% | 1.3% | 2.3% | 1.2% | 0.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $91.2B | $95.4B | $97.7B | $94.6B | $98.9B | $102.9B | $105.7B | $100.4B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $3.0B | $832.0M | $2.4B | $3.4B | $2.4B | -$3.2B | $2.1B | $4.7B |
| Net income | $1.8B | $87.0M | $1.6B | $1.8B | $1.0B | -$4.0B | $2.9B | $2.9B |
| Diluted EPS | $1.41 | $0.07 | $1.30 | $1.41 | $0.80 | -$3.13 | $2.31 | $2.30 |
| Operating cash flow | $3.1B | -$745.0M | $1.9B | $4.6B | $1.9B | $796.0M | $3.4B | $4.2B |
| Free cash flow | $2.5B | -$1.4B | $1.1B | $3.8B | $1.3B | $98.0M | $2.6B | $3.4B |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 3.3% | 0.9% | 2.4% | 3.6% | 2.4% | -3.1% | 2.0% | 4.7% |
| Net margin | 1.9% | 0.1% | 1.7% | 1.9% | 1.0% | -3.9% | 2.8% | 2.9% |
Company news
Jul 20, 2026
Jul 17, 2026
- 2d agoWhat A Patient Holder Is Really Paying For CVS Health Stocktrefis.com
- 2d agoWhat's A Strong Quarter Worth When Elevance Health Is Ditching Its Own Markets?trefis.com
- 3d agoCVS Health (CVS) Opens Its First Neighborhood Pharmacy In Houstonfinance.yahoo.com
- 3d agoCVS Health CEO David Joyner warns private insurers won't cover GLP-1s for weight loss until drug prices dropfinance.yahoo.com
- 3d agoCVS Pharmacy® celebrates opening of first pharmacy-focused location in Houstonfinance.yahoo.com
- 3d agoHow Much Of Your Portfolio Is Really CVS?trefis.com
- 3d agoCVS Health (CVS) Stock Looks Pricey On FTC Insulin Settlementfinance.yahoo.com
- 3d agoHow Investors May Respond To CVS (CVS) Dividend Move And GLP‑1 Strategy Across Its Health Platformfinance.yahoo.com
Jul 16, 2026
- 3d agoUnitedHealth Jumps 10.3% After Raising 2026 EPS Outlook Above Estimatesfinance.yahoo.com
- 4d agoCan Higher Occupancy Offset Lower Admissions in CYH's Q2 Earnings?finance.yahoo.com
- 4d agoAbbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-marketfinance.yahoo.com
- 4d agoDanaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-26 | Clark James David· SVP, Cont & Chief Acct Officer | Tax withholding | 454 | $90.98 | $41,304.92 | filing |
| 2026-05-31 | Compton-Phillips Amy· EVP, Chief Medical Officer | Tax withholding | 7,618 | $90.98 | $693,085.64 | filing |
| 2026-05-31 | Newman Brian· EVP, Chief Financial Officer | Tax withholding | 2,478 | $90.98 | $225,448.44 | filing |
| 2026-05-21 | ROBBINS LARRY | Sale | 370,462 | $93.45 | $34.6M | filing |
| 2026-05-21 | AGUIRRE FERNANDO | D | 1,563 | $93.50 | $146,142.06 | filing |
| 2026-05-20 | ROBBINS LARRY | Sale | 797,628 | $93.48 | $74.6M | filing |
| 2026-05-20 | ROBBINS LARRY | Sale | 152,691 | $94.81 | $14.5M | filing |
| 2026-05-20 | ROBBINS LARRY | Sale | 66,881 | $95.67 | $6.4M | filing |
| 2026-05-20 | AGUIRRE FERNANDO | D | 30,437 | $93.78 | $2.9M | filing |
| 2026-05-20 | ROBBINS LARRY | Sale | 800 | $96.28 | $77,025.52 | filing |
| 2026-05-19 | ROBBINS LARRY | Sale | 1,983,387 | $94.45 | $187.3M | filing |
| 2026-05-19 | ROBBINS LARRY | Sale | 151 | $95.18 | $14,372.18 | filing |
| 2026-05-14 | Balser Jeffrey R. | Award | 2,058 | $97.15 | $199,934.70 | filing |
| 2026-05-14 | AGUIRRE FERNANDO | Award | 1,563 | $97.15 | $151,845.45 | filing |
| 2026-05-14 | BROWN C DAVID II | Award | 1,544 | $97.15 | $149,999.60 | filing |
| 2026-05-14 | KIRBY J SCOTT | Award | 1,447 | $97.15 | $140,576.05 | filing |
| 2026-05-14 | Norwalk Leslie V | Award | 1,447 | $97.15 | $140,576.05 | filing |
| 2026-05-14 | SANSONE GUY P | Award | 1,447 | $97.15 | $140,576.05 | filing |
| 2026-05-08 | Mandadi Tilak· EVP, Chief Exp & Tech Officer | Sale | 69,551 | $89.58 | $6.2M | filing |
| 2026-04-01 | Joyner J. David· President, CEO and Chair | Tax withholding | 8,029 | $72.49 | $582,022.21 | filing |
| 2026-04-01 | Mandadi Tilak· EVP, Chief Exp & Tech Officer | Tax withholding | 3,634 | $72.49 | $263,428.66 | filing |
| 2026-04-01 | Khichi Samrat S.· EVP, CPO and General Counsel | Tax withholding | 3,541 | $72.49 | $256,687.09 | filing |
| 2026-04-01 | Clark James David· SVP, Cont & Chief Acct Officer | Tax withholding | 3,262 | $72.49 | $236,462.38 | filing |
| 2026-04-01 | Nelson Steven H· EVP and President, Aetna | Tax withholding | 2,432 | $72.49 | $176,295.68 | filing |
| 2026-04-01 | Shah Prem S· EVP and Group President | Tax withholding | 1,484 | $72.49 | $107,575.16 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.